#USA #Boston #SOPHiA GENETICS #OncoPortal #Mutation Tracker

SOPHiA GENETICS Introduces Cutting-Edge OncoPortal™ Mutation Tracker

SOPHiA GENETICS, a recognized leader in healthcare technology, has announced the launch of its advanced OncoPortal™ Mutation Tracker. Designed to enhance cancer patient monitoring, this tool represents a significant step forward in the management of Measurable Residual Disease (MRD). This comprehensive solution is now integrated with the existing SOPHiA DDM™ Platform, marking a pivotal advancement in data-driven oncology.

The Importance of MRD Tracking in Oncology

In the realm of cancer care, the ability to track genetic mutations over time is increasingly critical. This allows clinicians to identify treatment resistance and monitor residual cancer cells more effectively. The OncoPortal™ Mutation Tracker enables healthcare professionals to track genomic variants at low frequencies across multiple intervals. By integrating this feature with next-generation sequencing technologies, the platform is capable of detecting cancer-specific mutations with enhanced precision.

Dr. Philippe Menu, Chief Medical Officer at SOPHiA GENETICS, commented on the impact of this new tool, stating, "The ability to reliably track low frequency variants longitudinally is a game-changer because it allows the detection of even the smallest traces of cancer that can evade traditional methods of testing and ultimately drive relapse."

Key Features of the OncoPortal™ Mutation Tracker

1. Longitudinal Tracking: The new module allows for comprehensive tracking of evolving genomic variants, thus providing clinical researchers with insights into disease progression.
2. Flexibility and Customization: Users can customize threshold settings and reporting features, enabling them to choose which low frequency variants to monitor.
3. Visual Representation: By providing graphical representations of genetic changes over time, the platform simplifies the analysis process, enhancing the efficiency of workflows in clinical settings.

Enhanced Patient Outcomes

The OncoPortal™ Mutation Tracker is designed to empower healthcare professionals by facilitating early identification of emerging variants and residual diseases. Tailoring treatment plans to a patient’s unique genomic profile may lead to significantly improved long-term outcomes. Dr. Christophe Marzac from the Gustave Roussy Institute highlighted the system's potential: "This longitudinal interface represents the solution we've been seeking to unite our oncologists in embracing broader adoption of NGS. It's the missing piece that unlocks a new frontier in personalized, data-driven medicine."

Conclusion

SOPHiA GENETICS' OncoPortal™ Mutation Tracker is paving the way for improved cancer care through enhanced monitoring capabilities. As healthcare continues to evolve with data-driven medicine, tools like this offer the promise of more personalized, efficient, and effective treatment strategies. For more details on this innovative product, visit SOPHiAGENETICS.com.

SOPHiA GENETICS remains committed to expanding access to genomic data worldwide, providing actionable insights that continue to redefine patient care standards.

Note: SOPHiA GENETICS products are for research use only and not for diagnostic procedures unless specified otherwise.